We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Cyclophilin D Inhibitors May Protect Heart Cells

By Biotechdaily staff writers
Posted on 20 Apr 2005
Researchers have identified a protein linked to the death of heart cells that occurs when oxygen flow is re-established to areas in the heart that have experienced oxygen deficiency during a heart attack.

"When a person comes to a hospital and it is realized that he or she is having a heart attack or stroke, one of the first things done is to re-establish blood flow,” explained senior author Dr. More...
Jeffery Molkentin, an associate professor in the division of molecular cardiovascular biology at Cincinnati Children's Hospital Medical Center (Ohio, USA). "At this point, cells have not yet died. But when flow is re-established there is a huge burst of reactive oxygen, and that's when cells die. We hypothesize that if, at the same time you re-establish flow you infuse a cyclophilin D inhibitor, you might profoundly affect the heart or brain and, presumably, protect it.”

Cyclophilin D is a prolyl isomerase located within the mitochondrial matrix and is produced by the Ppif gene. The investigators genetically engineered two lines of mice, one line lacking Ppif and another of mice overexpressing cyclophilin D in the heart.

Results published in the March 31, 2005, issue of Nature revealed that mice lacking Ppif were protected from reactive oxygen burst-induced cell death, whereas cyclophilin D-overexpressing mice showed mitochondrial swelling and spontaneous cell death. Mitochondria isolated from the livers, hearts, and brains of mice lacking Ppif were resistant to mitochondrial swelling and permeability transition, and primary hepatocytes and fibroblasts isolated from these animals were largely protected from calcium ion-overload and oxidative stress-induced cell death.

Drugs such as cyclosporine that block cyclophilin D activity are already available but have not yet been tested in humans for this purpose. "Our study suggests that these drugs should be re-evaluated for injury related to loss of blood flow,” said Dr. Molkentin. "Although our study was in a mouse model and looked at the heart, studies in cell culture indicate similar benefits when blood flow causes injury to the brain, kidney, and liver.”




Related Links:
Cincinnati Children's Hospital Medical Center

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Spinal Fluid Cell Count Control
Spinalscopics
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.